When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BPMC - Blueprint Medicines lead drug flunks GIST study; shares down 15% premarket
Blueprint Medicines Corporation
Blueprint Medicines (NASDAQ:BPMC) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER, evaluating lead candidate avapritinib, branded as Ayvakit, in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) failed to achieve the primary endpoint of demonstrating an improvement in progression-free survival (PFS) compared to Bayer's (OTCPK:BAYRY) Stivarga (regorafenib).
More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Healthcare stocks news, Stocks on the move,